ListarArtículos (Medicina) por materia "Lenalidomide plus R-GDP (R2-GDP)"
Mostrando ítems 1-1 de 1
-
Artículo
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
(AMER ASSOC CANCER RESEARCH, 2022)Purpose: New therapeutic options are needed in relapsed/refrac tory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide ...